Figuring out how to combine different IO approaches will take time so what have we learned lately?
PARP plus IO and IO combos are becoming all the rage, what can we learn from early signals?
A look at Dr Malcolm Brenner's work on virus specific T cell therapies
At ASCO-SITC this weekend there was some compelling new scientific data highlighting subsets of patients who might be eligible for cancer immunotherapy, including novel combination approaches.
6 key trends and highlights of note from the inaugural ASCO-SITC meeting in Orlando, Florida
A look at another surprising factor that might affect efficacy of cancer immunotherapy and checkpoint blockade.
After JAK1/2 upregulation and PTEN loss, a third mechanism of resistance to checkpoint blockade has been identified. We discuss the issues around this latest challenge...